Scrapie

Treatment of mice infected with prions used a CpG Immunomodulator

Published in Vector and Zoonosis Week, August 19th, 2002

Coley Pharmaceutical Group, Inc., announced the publication of a fast-track research letter entitled "Postexposure prophylaxis against prion disease with a stimulator of innate immunity" in the July 2002 issue of The Lancet.

Investigators at the Institute of Neuropathology, Ludwig-Maximilians University, Munich (Shneh Sethi, MD, and Hans Kretzschmar, MD) and at the Technical University of Munich (Hermann Wagner, MD, PhD), as well as Coley scientist Grayson Lipford, PhD, report the prevention of scrapie development by treating infected mice with repeated injections of a CpG molecule

Scrapie is a fatal, degenerative disease affecting the central...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vector and Zoonosis Week

Source: Vector and Zoonosis Week (2002-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry